Ashley Hall
CIK 1801842 · Chief Development Officer · last filed 2026-03-23
Ashley Hall is a Chief Development Officer who has filed 9 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for GPCR, was dated Mar 23, 2026. Across all open-market trades the lifetime net is −$98.1K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.73M
3
9
-$98.1K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GPCR | Chief Development Officer | 155,187 | $42.93 | $6.66M | $0 | 5 | 2026-03-23 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | Chief Development Officer | 39,600 | $18.20 | $720.7K | -$98.1K | 3 | 2023-08-29 |
| ESPR | Chief Development Officer | 22,500 | $3.15 | $70.9K | $0 | 1 | 2021-01-29 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-23 | GPCR | Grant (A) | +47,706 | $0 | EDGAR |
| 2026-03-05 | GPCR | Mixed | −4,836 | -$101.5K | EDGAR |
| 2025-09-22 | GPCR | Tax (F) | −6,021 | -$46.6K | EDGAR |
| 2025-03-18 | GPCR | Grant (A) | +51,048 | $0 | EDGAR |
| 2024-09-20 | GPCR | Grant (A) | +67,290 | $0 | EDGAR |
| 2023-08-29 | OnKure Therapeutics, Inc. (RPHM) Delisted | Mixed | — | -$69.9K | EDGAR |
| 2022-12-13 | OnKure Therapeutics, Inc. (RPHM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-15 | OnKure Therapeutics, Inc. (RPHM) Delisted | Grant (A) | +30,000 | $0 | EDGAR |
| 2021-01-29 | ESPR | Grant (A) | +7,000 | $0 | EDGAR |